Fig. 3.6.

Nanoparticle siRNA delivery for tumor treatment. a N2Atumor-bearing mice received a single intravenous injection of 40 mg pLuc in RPP-nanoplexes only, with control siRNA or with Luc-specific siRNA. 24 h following administration, tissues were assayed for luciferase activity (n = 5). b Mice were inoculated withN2Atumor cells and left untreated (open squares) or treated every 3 days by tail vein injection with RPP-nanoplexes with control siRNA or VEGF R2-specific siRNA at a dose of 40 mg per mouse. Treatment was started when the tumors became palpable (>20 mm³). Only VEGF R2-sequence-specific siRNA inhibited tumor growth, whereas treatment with control siRNA did not affect tumor growth rate when compared with untreated controls (n = 5)